



## Press Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Sunao Manabe, Representative Director, President and COO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Junichi Onuma,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<https://www.daiichisankyo.com>

### **Daiichi Sankyo Launches “MINNEBRO® Tablets” in Japan**

**Tokyo, Japan (May 13, 2019)** – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the launch in Japan of MINNEBRO® Tablets 1.25 mg, 2.5 mg and 5 mg (generic name: esaxerenone; hereafter, the drug).

The drug is a novel, non-steroidal, selective mineralocorticoid receptor<sup>\*1</sup> blocker identified during the research collaboration with Exelixis, Inc. (based in Alameda, California, U.S.), and has subsequently been developed by Daiichi Sankyo independently. Marketing approval for the indication of hypertension was received in January, 2019, on the basis of the results of a domestic phase 3 clinical trial (ESAX-HTN study) in patients with essential hypertension<sup>\*2</sup>.

Daiichi Sankyo expects the drug to benefit patients by providing a new therapeutic option for the treatment of hypertension.

### Product outline

Brand name	MINNEBRO® Tablets 1.25 mg, 2.5 mg, 5 mg
Generic name (JAN)	Esaxerenone
Indication	Hypertension
Dosage and administration	The recommended oral dose of esaxerenone is 2.5 mg once daily. The dose for patients with an inadequate response can be increased up to 5 mg once daily.
Drug price	MINNEBRO® Tablets 1.25mg: 46.90 yen/tablet MINNEBRO® Tablets 2.5mg: 89.90 yen/tablet MINNEBRO® Tablets 5mg: 134.90 yen/tablet
Date of approval for manufacturing and marketing	January 8, 2019
Date of listing in the NHI Price	February 26, 2019
Date of launch	May 13, 2019
Manufacture and Marketing	Daiichi Sankyo Company, Limited

#### **\*1 Mineralocorticoid receptor**

The mineralocorticoid receptor is a receptor for steroid hormones that control the blood's electrolyte balance. Excessive activation of mineralocorticoid receptors has been found to be involved in hypertension.

#### **\*2 Essential hypertension**

Essential hypertension is the major form of hypertension accounting for 90% of hypertensive patients and is associated with heterogeneous factors like genetics and lifestyle habits, while secondary hypertension is the result of identified underlying disease factors.

#### **About Daiichi Sankyo**

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: [www.daiichisankyo.com](http://www.daiichisankyo.com)